Intravitreal Aflibercept Injection 2mg

DRUG2 trials

Sponsors

Regeneron Pharmaceuticals, Tennessee Retina

Conditions

Neovascular Age-related Macular Degeneration

Phase 3

Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular (Wet) Age-related Macular Degeneration (AMD)

CompletedNCT00964795

Regeneron PharmaceuticalsNeovascular Age-related Macular Degeneration

Start: 2009-12-31End: 2013-08-31Updated: 2015-03-23

Phase 4

Two-week Retreatment Interval Study for Treated Age-related Macular Degeneration Refractory to Monthly Aflibercept

Tennessee RetinaNeovascular Age-related Macular Degeneration

Start: 2018-04-30End: 2019-07-31Target: 22Updated: 2018-04-20